Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer
Author:
- 1 February 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 26 (1) , 3-8
Abstract
Ovarian cancer is the commonest gynaecological cancer and the fifth leading cause of cancer death in women worldwide. The majority of patients with ovarian cancer present at an advanced stage, and up to 70% of those treated with a curative approach eventually recur and succumb to their disease. This article examines the management of ovarian cancer over the years and the role of intraperitoneal chemotherapy in the treatment algorithm. The surgical paradigm for ovarian cancer has changed and the goal is optimal cytoreduction with no residual disease. Intraperitoneal chemotherapy has been found to be superior to intravenous treatment alone, and the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has produced encouraging results with improved disease-free and overall survivals at acceptable morbidity and mortality rates. The most important prognostic factor for ovarian cancer survival is the ability to achieve optimal cytoreduction with no residual disease. CRS and HIPEC should be considered as an option for the management of advanced ovarian cancer and further trials are required to determine its role in both the primary and recurrent settings.Keywords
This publication has 28 references indexed in Scilit:
- Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysisGynecologic Oncology, 2013
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- Editorial: Advances in Epithelial Ovarian Cancer TherapyCurrent Pharmaceutical Design, 2012
- Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian CancerAnnals of Surgical Oncology, 2012
- Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining ‘optimal’ residual diseaseGynecologic Oncology, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- First-Line Therapy in Ovarian Cancer TrialsInternational Journal of Gynecological Cancer, 2011
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2010
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009